Enhancement of RNA properties via in vitro transcription priming
A new molecular tool utilising in vitro transcription priming to modify RNA, enhancing its stability and translation, and allowing its detection.
Applications: Cap-independently translated mRNA, Therapeutic vaccines, Gene therapies, Cancer immunotherapies, Regulatory control of protein expression, mRNA screening, mRNA detection, mRNA delivery
| Features | Benefits |
|---|---|
| Use of an azido-functionalised dinucleotide in vitro transcription primer, CleaN3, that relies on base-pairing with T7 RNA polymerase promoters leads to high priming efficiencies and in vitro transcription yields | Superior in vitro transcription yields, priming efficiencies, and primed transcript homogeneities over existing primers for cap-independently translated mRNAs, and non-coding RNAs |
| The 5′ azide present in CleaN3-primed transcripts, provides access to post-transcriptional modification via click chemistry, e.g., strain-promoted azide-alkyne cycloaddition (SPAAC) | A rapid and efficient process over existing synthesis processes – one working day to synthesis 5’ modified transcripts from nucleoside triphosphates; Click chemistry permits improvements to properties of cap-independently translated mRNAs |
| Enhanced linear cap-independently translated (CIT) mRNA properties, such as translation efficiency and stability without eliciting immunogenicity | Enables production of therapeutic mRNA designs to target diseases, such as cancers; Spatiotemporal characterisation of CIT mRNA uptake and cellular fate |
| Convenient benchmarking of internal ribosome entry sites (IRESs) and cap-independent translational enhancers (CITEs) independent of cell line-specific factors, which is currently challenging |
Awaiting patent and Available For
- Co-development
- Consulting
- Licensing